These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
230 related articles for article (PubMed ID: 30136349)
1. Comparative oncology: The paradigmatic example of canine and human mast cell neoplasms. Willmann M; Hadzijusufovic E; Hermine O; Dacasto M; Marconato L; Bauer K; Peter B; Gamperl S; Eisenwort G; Jensen-Jarolim E; Müller M; Arock M; Vail DM; Valent P Vet Comp Oncol; 2019 Mar; 17(1):1-10. PubMed ID: 30136349 [TBL] [Abstract][Full Text] [Related]
2. "Masitinib" is safe and effective for the treatment of canine mast cell tumors. Gentilini F J Vet Intern Med; 2010; 24(1):6; author reply 7. PubMed ID: 20391634 [No Abstract] [Full Text] [Related]
3. The JAK2/STAT5 signaling pathway as a potential therapeutic target in canine mastocytoma. Keller A; Wingelhofer B; Peter B; Bauer K; Berger D; Gamperl S; Reifinger M; Cerny-Reiterer S; Moriggl R; Willmann M; Valent P; Hadzijusufovic E Vet Comp Oncol; 2018 Mar; 16(1):55-68. PubMed ID: 28397975 [TBL] [Abstract][Full Text] [Related]
4. Combination CCNU and vinblastine chemotherapy for canine mast cell tumours: 57 cases. Cooper M; Tsai X; Bennett P Vet Comp Oncol; 2009 Sep; 7(3):196-206. PubMed ID: 19691648 [TBL] [Abstract][Full Text] [Related]
5. Synergistic antiproliferative effects of KIT tyrosine kinase inhibitors on neoplastic canine mast cells. Gleixner KV; Rebuzzi L; Mayerhofer M; Gruze A; Hadzijusufovic E; Sonneck K; Vales A; Kneidinger M; Samorapoompichit P; Thaiwong T; Pickl WF; Yuzbasiyan-Gurkan V; Sillaber C; Willmann M; Valent P Exp Hematol; 2007 Oct; 35(10):1510-21. PubMed ID: 17681669 [TBL] [Abstract][Full Text] [Related]
6. Masitinib is safe and effective for the treatment of canine mast cell tumors. Hahn KA; Ogilvie G; Rusk T; Devauchelle P; Leblanc A; Legendre A; Powers B; Leventhal PS; Kinet JP; Palmerini F; Dubreuil P; Moussy A; Hermine O J Vet Intern Med; 2008; 22(6):1301-9. PubMed ID: 18823406 [TBL] [Abstract][Full Text] [Related]
7. A retrospective review of treatment and response of high-risk mast cell tumours in dogs. Miller RL; Van Lelyveld S; Warland J; Dobson JM; Foale RD Vet Comp Oncol; 2016 Dec; 14(4):361-370. PubMed ID: 25223579 [TBL] [Abstract][Full Text] [Related]
8. Expression of c-kit proto-oncogene in canine mastocytoma: a kinetic study using real-time polymerase chain reaction. Turin L; Acocella F; Stefanello D; Oseliero A; Fondrini D; Brizzola S; Riva F J Vet Diagn Invest; 2006 Jul; 18(4):343-9. PubMed ID: 16921872 [TBL] [Abstract][Full Text] [Related]
9. Is lymph node metastasis of canine grade 2 MCTs justification for adjuvant therapy? Schulman FY Vet Comp Oncol; 2015 Jun; 13(2):151. PubMed ID: 25968074 [No Abstract] [Full Text] [Related]
10. Vinblastine and prednisolone as adjunctive therapy for canine cutaneous mast cell tumors. Davies DR; Wyatt KM; Jardine JE; Robertson ID; Irwin PJ J Am Anim Hosp Assoc; 2004; 40(2):124-30. PubMed ID: 15007048 [TBL] [Abstract][Full Text] [Related]
11. Heterogeneity of internal tandem duplications in the c-kit of dogs with multiple mast cell tumours. Amagai Y; Tanaka A; Matsuda A; Jung K; Oida K; Nishikawa S; Jang H; Matsuda H J Small Anim Pract; 2013 Jul; 54(7):377-80. PubMed ID: 23614673 [TBL] [Abstract][Full Text] [Related]
12. Targeting of heat-shock protein 32/heme oxygenase-1 in canine mastocytoma cells is associated with reduced growth and induction of apoptosis. Hadzijusufovic E; Rebuzzi L; Gleixner KV; Ferenc V; Peter B; Kondo R; Gruze A; Kneidinger M; Krauth MT; Mayerhofer M; Samorapoompichit P; Greish K; Iyer AK; Pickl WF; Maeda H; Willmann M; Valent P Exp Hematol; 2008 Nov; 36(11):1461-70. PubMed ID: 18723263 [TBL] [Abstract][Full Text] [Related]
13. Identification of additional mitochondrial DNA mutations in canine mast cell tumours. Śmiech A; Ślaska B; Surdyka M; Grzybowska-Szatkowska L; Łopuszyński W; Różańska D Acta Vet Scand; 2016 May; 58(1):28. PubMed ID: 27146669 [TBL] [Abstract][Full Text] [Related]
14. Susceptibility of the C2 canine mastocytoma cell line to the effects of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). Elders RC; Baines SJ; Catchpole B Vet Immunol Immunopathol; 2009 Jul; 130(1-2):11-6. PubMed ID: 19185923 [TBL] [Abstract][Full Text] [Related]
15. Canine mast cell tumours: a review of the pathogenesis, clinical features, pathology and treatment. Welle MM; Bley CR; Howard J; Rüfenacht S Vet Dermatol; 2008 Dec; 19(6):321-39. PubMed ID: 18980632 [TBL] [Abstract][Full Text] [Related]
16. Evaluation of histological grade and histologically tumour-free margins as predictors of local recurrence in completely excised canine mast cell tumours. Donnelly L; Mullin C; Balko J; Goldschmidt M; Krick E; Hume C; Brown DC; Sorenmo K Vet Comp Oncol; 2015 Mar; 13(1):70-6. PubMed ID: 23451809 [TBL] [Abstract][Full Text] [Related]
17. KIT polymorphisms and mutations determine responses of neoplastic mast cells to bafetinib (INNO-406). Peter B; Hadzijusufovic E; Blatt K; Gleixner KV; Pickl WF; Thaiwong T; Yuzbasiyan-Gurkan V; Willmann M; Valent P Exp Hematol; 2010 Sep; 38(9):782-91. PubMed ID: 20685234 [TBL] [Abstract][Full Text] [Related]
18. Clinical efficacy and safety of a water-soluble micellar paclitaxel (Paccal Vet) in canine mastocytomas. Rivera P; Akerlund-Denneberg N; Bergvall K; Kessler M; Rowe A; Willmann M; Persson G; Kastengren Fröberg G; Westberg S; von Euler H J Small Anim Pract; 2013 Jan; 54(1):20-7. PubMed ID: 23190121 [TBL] [Abstract][Full Text] [Related]
19. HSP32 and HSP90 Immunoexpression, in Relation to Kit Pattern, Grading, and Mitotic Count in Canine Cutaneous Mast Cell Tumors. Romanucci M; Massimini M; Ciccarelli A; Malatesta D; Bongiovanni L; Gasbarre A; Della Salda L Vet Pathol; 2017 Mar; 54(2):222-225. PubMed ID: 27627984 [TBL] [Abstract][Full Text] [Related]